

Table of Contents

About the Contributors	vii
Acknowledgments	xvii
Introduction	xix
Table of Chapters	xxvii

PART I: PROCESS

Chapter 1 Internal Investigation of Suspected Wrongdoing by Corporate Employees

§ 1:1	Introduction	1-2
§ 1:2	Steps to Take at the Outset of an Investigation.....	1-3
§ 1:2.1	Who Conducts the Investigation—In-House Counsel or Outside Attorneys?	1-3
§ 1:2.2	Defining the Scope of the Investigation	1-4
§ 1:2.3	Doing a Conflicts Check.....	1-5
§ 1:2.4	Expertise of Counsel	1-6
§ 1:3	Investigative Tools	1-7
§ 1:3.1	Document Holds, Collection and Review	1-7
§ 1:3.2	Recovering Expenses Incurred During Internal Investigations	1-9
§ 1:3.3	Employee Interviews.....	1-10
[A]	Presence of In-House Counsel at the Interview.....	1-10
[B]	Conducting the Interview	1-11
[C]	Separate Counsel for the Employee.....	1-13
§ 1:3.4	Whether to Prepare a Written Report	1-15
§ 1:3.5	Polygraph Testing.....	1-16
§ 1:3.6	Workplace Searches	1-17
§ 1:3.7	Workplace Surveillance	1-18
§ 1:3.8	Drug and Alcohol Testing	1-18
§ 1:4	Attorney-Client Privilege and Attorney Work-Product Protection Regarding Internal Investigations	1-19

§ 1:5	Obstruction of Justice	1-21
§ 1:5.1	Obstruction of Justice Statutes	1-22
§ 1:5.2	Liability of Attorneys	1-25
§ 1:5.3	Guidelines for Counsel	1-26
§ 1:6	Subpoenas and Review of Documents Located Overseas	1-27
§ 1:6.1	Obstruction of Justice in International Cases	1-28
§ 1:7	Indemnification and Advancement of Legal Fees	1-29
§ 1:7.1	Mandatory Indemnification	1-29
§ 1:7.2	Permissive Indemnification	1-31
§ 1:7.3	Advancement of Legal Fees and Expenses	1-32
§ 1:7.4	Constitutional Issues	1-33
§ 1:8	Protection for Whistleblowers Against Retaliation	1-35
§ 1:8.1	FCA Anti-Retaliation Protections	1-35
§ 1:8.2	Sarbanes-Oxley Whistleblower Protections	1-36
§ 1:8.3	Retaliation Policies	1-37
§ 1:8.4	Disciplining Whistleblowers	1-38
§ 1:8.5	Separation/Confidentiality Agreements	1-38
§ 1:9	Practitioner’s Checklist for Conducting Internal Investigations	1-40

Chapter 2 The Attorney-Client Privilege, Work-Product Protection, and Self-Critical Privilege in Internal Investigations

§ 2:1	Introduction	2-2
§ 2:2	The Attorney-Client Privilege	2-2
§ 2:2.1	Elements of the Corporate Attorney-Client Privilege	2-3
§ 2:2.2	Applicability to Experts, Attorney Agents, and the Corporation’s Former Employees	2-4
§ 2:2.3	Attorney’s Duty to Assert Privilege	2-6
§ 2:2.4	What the Privilege Does Not Cover	2-6
§ 2:2.5	The Crime-Fraud Exception	2-8
§ 2:2.6	Authority to Waive the Corporate Attorney-Client Privilege	2-11
§ 2:2.7	Effect of Inadvertent Disclosure of Privileged Information on Waiver	2-11
§ 2:3	Work-Product Protection	2-15
§ 2:3.1	Work-Product Protection Qualified	2-16
§ 2:3.2	Applicability to Materials from an Internal Investigation	2-16
§ 2:3.3	Materials Protected by the Work-Product Doctrine	2-17

Table of Contents

§ 2:3.4 Government Assertions of Work-Product
Protection over Investigative Materials 2-18

§ 2:4 The Department of Justice’s Waiver Policy and the
Sentencing Guidelines 2-18

§ 2:4.1 Evolution of DOJ Policy on Waiver of Privilege 2-19

§ 2:4.2 The Principles of Federal Prosecution of
Business Organizations..... 2-21

§ 2:4.3 The Yates Memo..... 2-24

§ 2:5 Disclosure to the Government and Its Impact on
Waiver of the Attorney-Client Privilege and
Work-Product Protection 2-27

§ 2:5.1 Attorney-Client Privilege and Selective Waiver..... 2-27

§ 2:5.2 Work-Product Protection and Selective Waiver..... 2-29

§ 2:6 The Common Interest Privilege..... 2-34

§ 2:6.1 Applicability of the Common Interest Privilege..... 2-34

§ 2:7 Self-Critical Privilege 2-36

§ 2:7.1 Recognition of the Self-Critical Privilege 2-37

§ 2:7.2 Rejection of the Self-Critical Privilege 2-38

§ 2:8 Additional Practical Waiver Problems in Internal
Investigations 2-40

§ 2:8.1 Internal Investigations Because of Business
Necessities 2-40

§ 2:8.2 Investigation by and for Management..... 2-41

§ 2:8.3 Use of Regularly Employed Auditor 2-42

§ 2:8.4 The Pseudo-Hypothetical 2-43

§ 2:8.5 Disclosures to Public Relations Consultants..... 2-43

§ 2:9 Practitioner’s Checklist for Obtaining Benefits of
Cooperation Without Waiver 2-46

Chapter 3 Responding to Searches and Seizures

§ 3:1 Search Warrants..... 3-2

§ 3:1.1 Generally 3-2

§ 3:1.2 Specifics of a Search Warrant 3-2

§ 3:1.3 Execution of the Warrant 3-4

§ 3:1.4 Effects of Search and Seizure on Corporations 3-5

§ 3:2 Searching and Seizing Electronic Data 3-8

§ 3:2.1 Warrantless Computer Searches and Seizures..... 3-9

[A] Exigent Circumstances 3-9

[B] Consent 3-9

[C] “Plain View” Exception..... 3-11

[D] Searches at Border Crossings 3-12

[E] Exceptions Regarding IP Addresses and
Cell Phone Locators..... 3-14

§ 3:2.2	Warrants to Search Computers and Other Electronic Devices	3-16
[A]	Computer Searches that Go Beyond the Scope of the Warrant.....	3-19
[B]	Cell Phone Searches.....	3-20
[C]	Time Limits for Government Seizures of Electronic Information.....	3-20
§ 3:2.3	Out-of-District/-Country Warrants	3-21
§ 3:2.4	Data Privacy and Access	3-22
§ 3:3	Searching and Seizing Other Electronic Communications.....	3-23
§ 3:3.1	Wiretapping.....	3-23
§ 3:3.2	Intercepting Text Messages and Emails.....	3-24
§ 3:3.3	GPS Tracking.....	3-25
§ 3:4	Protecting Privileged Documents During a Search.....	3-28
§ 3:5	Practitioner’s Checklist for Responding to Searches and Seizures	3-29

Chapter 4 Grand Jury Investigations and Multiple Representations of Witnesses

§ 4:1	Overview of the Grand Jury Process.....	4-2
§ 4:1.1	Responding to a Grand Jury Subpoena.....	4-3
[A]	Litigation Holds.....	4-3
[B]	Insurance Considerations	4-4
[C]	Review of Relevant Documents.....	4-5
[D]	Unduly Broad Subpoenas.....	4-6
[E]	Discoverability of Documents Subject to Protective Orders	4-6
§ 4:1.2	Motions to Quash Grand Jury Subpoenas.....	4-7
§ 4:1.3	Computer Records and Electronic Documents.....	4-8
§ 4:1.4	Subpoena Compliance and Data Privacy Laws.....	4-11
§ 4:1.5	Motions to Dismiss Grand Jury Indictments.....	4-13
§ 4:1.6	Parallel Proceedings.....	4-16
§ 4:2	Ethical Issues in Multiple Representations Before a Grand Jury	4-17
§ 4:2.1	Ethical Considerations and Conflicts of Interest	4-18
§ 4:2.2	New York’s Attorney Ethics Rules.....	4-25
§ 4:2.3	The Prosecutor’s Response	4-26
§ 4:2.4	A Carefully Thought-Out Decision	4-28
§ 4:2.5	The Judicial Response.....	4-28
§ 4:3	Practical Considerations When Considering Multiple Representation	4-30

Table of Contents

Chapter 5 Advising Witnesses in Light of Perjury Statutes

§ 5:1 Introduction 5-1
 § 5:1.1 Federal Perjury Statutes 5-2
 § 5:1.2 Distinctions Between Sections 1621 and 1623 5-4
 § 5:1.3 False Statements Statute..... 5-5
§ 5:2 Materiality 5-9
 § 5:2.1 Standard for Materiality..... 5-9
 § 5:2.2 Literal Truth Defense..... 5-11
§ 5:3 Perjury Prosecution Absent Prosecution for the
 Underlying Offense..... 5-15
§ 5:4 Dangers of Crossing the Line..... 5-18
§ 5:5 Perjury Traps..... 5-20
§ 5:6 Conclusion 5-22

**Chapter 6 Representing Companies and Individuals in SEC
 Investigations and Parallel Proceedings**

§ 6:1 SEC Investigations..... 6-2
 § 6:1.1 Enforcement Scheme 6-3
 [A] Authority and Powers of the Division of
 Enforcement 6-3
 [B] Civil Suits in Federal Courts Versus
 Administrative Proceedings 6-4
 [C] Criminal Enforcement Through DOJ/Parallel
 Proceedings..... 6-6
 § 6:1.2 How Investigations Arise/Whistleblower
 Program 6-6
 [A] Origins of Investigations..... 6-6
 [B] The Whistleblower Program 6-7
 [C] Retaliation Against Whistleblowers 6-9
 [D] Whistleblower Awards 6-11
 § 6:1.3 Responding to Investigative Requests—Initial
 Considerations 6-12
 [A] Initial Contact with the Staff..... 6-12
 [B] Conducting an Inquiry into the Facts 6-13
 [C] Assessing the Facts and Taking
 Appropriate Steps..... 6-15
 § 6:1.4 The Investigative Process..... 6-16
 [A] Informal Inquiries and Formal Investigations..... 6-16
 [B] Document Preservation, Collection,
 Review, and Production..... 6-17
 [C] Staff Interviews and Testimony..... 6-20

§ 6:1.5	Privilege Issues	6-22
[A]	Waiver of Privilege.....	6-22
[B]	Fifth Amendment Privilege.....	6-23
§ 6:1.6	Wells Submission Process	6-25
§ 6:1.7	Cooperation and the Seaboard Factors	6-26
§ 6:1.8	Charges and Remedies.....	6-31
§ 6:1.9	Settlement	6-38
§ 6:1.10	Recent Enforcement Trends	6-44
[A]	Increased Use of Whistleblowers	6-45
[B]	Increased Use of Data Analytics	6-45
[C]	Individual Accountability.....	6-46
[D]	Cyber Fraud	6-46
[E]	Investment Advisers and Private Equity Related Actions	6-51
§ 6:2	Parallel Proceedings	6-55
§ 6:2.1	General Strategic Issues and Considerations	6-55
§ 6:2.2	Admissibility of Statements Made During Parallel Civil Proceedings.....	6-57
§ 6:2.3	Wiretapping and Parallel Proceedings.....	6-60

Chapter 7 Corporate Compliance Programs Under the Organizational Sentencing Guidelines

§ 7:1	Introduction	7-2
§ 7:2	An Effective Program to Prevent and Detect Violations of Law	7-4
§ 7:2.1	Practical Considerations	7-4
§ 7:2.2	Requirements for an Effective Compliance and Ethics Program.....	7-5
[A]	Standards and Procedures	7-7
[B]	Top-Level Personnel Responsible.....	7-10
[C]	Exclusion of Individuals Who Present Known Risks.....	7-13
[D]	Communications and Training.....	7-15
[E]	Monitoring and Audits	7-17
[E][1]	Internal Auditing.....	7-17
[E][2]	Employee Hotlines and the Ombudsman	7-18
[E][3]	Business Ethics Questionnaires.....	7-19
[E][4]	Effectiveness Review.....	7-20
[F]	Incentives and Discipline.....	7-21
[G]	Ongoing Compliance Program Enhancements.....	7-22
[H]	Ongoing Risk Assessments	7-22
[I]	Other Guidance	7-23
§ 7:3	<i>Caremark</i> Liability.....	7-24

Chapter 8 Reserved

Chapter 9 Deferred Prosecution Agreements

§ 9:1 Introduction 9-1
§ 9:2 What Is a DPA? 9-9
§ 9:3 Why Has Deferred Prosecution of Corporations
 Become So Common?..... 9-13
§ 9:4 DPA or Declination?..... 9-17
§ 9:5 The Terms of the Agreement 9-19
§ 9:6 DOJ Guidance on the Use of Corporate Monitors 9-22
§ 9:7 Judicial Review of DPAs..... 9-27
§ 9:8 SEC’s Use of DPAs and NPAs..... 9-30
§ 9:9 Antitrust DPAs 9-33
§ 9:10 DPAs in the United Kingdom 9-35
§ 9:11 Practical Considerations in Negotiating Deferred
 Prosecution Agreements 9-38

**PART II: SELECTED SUBSTANTIVE
WHITE COLLAR CRIMINAL & REGULATORY ISSUES**

**Chapter 10 Representing the Drug or Medical Device
 Manufacturer in an Investigation**

§ 10:1 Introduction 10-2
§ 10:2 The Statutory and Regulatory Scheme..... 10-2
 § 10:2.1 The FDCA..... 10-2
 § 10:2.2 The Anti-Kickback Statute 10-3
 § 10:2.3 The False Claims Act..... 10-4
 § 10:2.4 The Foreign Corrupt Practices Act..... 10-4
 § 10:2.5 Other Regulatory Tools 10-4
 [A] Corporate Integrity Agreements..... 10-5
 [B] Exclusion from Federal Healthcare Programs 10-6
 [C] Fines 10-6
§ 10:3 Recent Developments in Enforcement Actions 10-7
 § 10:3.1 Enforcement Actions Against Pharmaceutical
 Manufacturers 10-7
 § 10:3.2 Enforcement Actions Against Medical Device
 Manufacturers 10-18
 § 10:3.3 Individual Accountability..... 10-21
 § 10:3.4 *Sorrell, Caronia*, and First Amendment
 Challenges 10-26

§ 10:4	FDA Warning and Untitled Letters to Pharmaceutical Companies Regarding Promotional Materials.....	10-32
§ 10:5	Compliance Strategies	10-36
§ 10:6	Conclusion	10-38

Chapter 11 Government Investigations Under the False Claims Act and Its Qui Tam Provisions

§ 11:1	Introduction	11-2
§ 11:2	The FCA Statute.....	11-4
§ 11:2.1	Liability and Damages Provisions	11-4
§ 11:2.2	Qui Tam Provisions	11-9
[A]	Complaint Filed Under Seal.....	11-9
[B]	Provisions Allowing Relators to Share in Monetary Recovery	11-11
[C]	Authority over Dismissal and Settlement	11-13
§ 11:3	Steps of a Government Investigation	11-15
§ 11:3.1	Agency Subpoenas	11-15
§ 11:3.2	Civil Investigative Demands.....	11-16
§ 11:3.3	The Government's Decision to Intervene.....	11-16
§ 11:4	Elements of FCA Liability.....	11-17
§ 11:4.1	False Claim.....	11-17
§ 11:4.2	Intent.....	11-21
§ 11:4.3	Materiality.....	11-24
§ 11:4.4	Causation	11-29
§ 11:5	FCA Issues in the Healthcare Area	11-30
§ 11:5.1	Off-Label Marketing.....	11-30
[A]	Generally	11-30
[B]	False Statements and First Amendment Issues.....	11-31
§ 11:5.2	Anti-Kickback Violations	11-35
§ 11:5.3	Pharmaceutical Pricing Cases	11-38
§ 11:5.4	Concealment of Safety Data and Risk Minimization.....	11-39
§ 11:5.5	Rule 9(b) Issues Involving Providers and Manufacturers	11-42
§ 11:5.6	Causation, Individualized Proof, and Damage Issues Involving Providers and Manufacturers	11-45
§ 11:6	FCA Issues Regarding Government Contractors.....	11-47
§ 11:6.1	Government Contractor Risks.....	11-47
§ 11:6.2	Combating Risk and Defending Claims.....	11-53
§ 11:6.3	Confronting Concurrent Proceedings.....	11-56
§ 11:7	Defenses	11-57
§ 11:7.1	Statute of Limitations.....	11-57
§ 11:7.2	Tax Code Cases.....	11-61

Table of Contents

§ 11:8 Special Defenses Against a Qui Tam Relator..... 11-61
 § 11:8.1 Public Disclosure Bar..... 11-62
 § 11:8.2 Original Source..... 11-68
 § 11:8.3 First-to-File Bar..... 11-73
§ 11:9 Protection of Whistleblower..... 11-76
§ 11:10 Other Whistleblower Laws..... 11-82
 § 11:10.1 Tax Whistleblower Law..... 11-82
 § 11:10.2 Securities Whistleblower Law..... 11-82

Chapter 12 Representation of Companies in Criminal Antitrust Investigations

§ 12:1 Introduction..... 12-2
§ 12:2 Elements of a Sherman Act Antitrust Criminal Prosecution..... 12-2
 § 12:2.1 Conspiracy..... 12-3
 § 12:2.2 Criminal Intent..... 12-4
 § 12:2.3 Interstate Nexus..... 12-5
 § 12:2.4 Statute of Limitations..... 12-5
§ 12:3 The Department of Justice Policy for Prosecution of Sherman Act Cases..... 12-7
§ 12:4 Criminal Penalties..... 12-10
 § 12:4.1 Individual Sentences..... 12-10
 [A] Sentencing of Individuals..... 12-10
 [B] Extradition of Foreign Executives..... 12-13
 [C] DOJ Carve-Out Policy..... 12-16
 § 12:4.2 Corporate Fines..... 12-17
 [A] Calculation of Fines..... 12-17
 [B] Largest Imposed Fines..... 12-21
 § 12:4.3 Major Ongoing Antitrust Investigations..... 12-22
 [A] Foreign Currency Exchange Investigation..... 12-22
 [B] Auto Parts Investigation..... 12-23
 [C] London Interbank Offered Rate (LIBOR) Investigation..... 12-27
 [D] Ocean Shipping Services Investigation..... 12-27
 [E] Electrolytic Capacitors Investigation..... 12-28
 [F] Generic Drugs Investigation..... 12-30
 [G] Packaged Seafood Investigation..... 12-31
 § 12:5 DOJ Corporate Leniency Policy..... 12-32
 § 12:5.1 Pre-Investigation Amnesty..... 12-34
 § 12:5.2 Alternative Grounds for Amnesty..... 12-35
 § 12:5.3 Antitrust Division’s 2008 Model Conditional Leniency Letters and FAQ..... 12-35
 § 12:5.4 Leniency for Corporate Directors, Officers, and Employees..... 12-37

§ 12:5.5 Potential Benefits of “Second-In” Cooperation 12-38
 § 12:6 Extraterritorial Application of U.S. Antitrust Laws..... 12-39
 § 12:7 State Antitrust Prosecutions 12-43
 § 12:8 Antitrust Compliance Strategies 12-46

Chapter 13 Asset Forfeiture and Debarment

§ 13:1 Asset Forfeiture 13-2
 § 13:1.1 The Civil Asset Forfeiture Reform Act of 2000 13-3
 § 13:1.2 Initiation of Civil Judicial Forfeiture 13-4
 [A] Pre-Seizure Warrant “Freezing” of Assets 13-4
 [B] Pre-Forfeiture Seizure of Assets..... 13-5
 [C] Pre-Trial Procedures Under Supplemental Rule G 13-5
 § 13:1.3 Civil Trial Procedure 13-10
 [A] Initial Burden on the Government..... 13-10
 [B] Innocent Owner Defense 13-10
 [C] Bona Fide Purchaser or Seller for Value 13-12
 [D] Knowledge or Reason to Believe Property Subject to Forfeiture..... 13-13
 [D][1] Willful Blindness 13-14
 [D][2] Knowledge in the Law Firm Fee Context 13-15
 [E] The Department of Justice Policy on Forfeiture of Attorney Fees 13-17
 [E][1] Department of Justice Policy on Federal Adoption 13-19
 [F] Use of Potentially Forfeitable Assets to Retain and Pay Counsel 13-21
 [F][1] Criminal Forfeitures 13-21
 [F][2] Civil Forfeitures 13-22
 [G] Excessive Fines Defense..... 13-23
 § 13:1.4 Civil Judicial Forfeiture of Transferred Traceable Assets..... 13-24
 § 13:1.5 Seizure of Fungible Assets..... 13-25
 § 13:1.6 Awards of Attorney Fees to Prevailing Claimants 13-26
 § 13:2 Debarment 13-28
 § 13:2.1 Overview of Suspension and Debarment 13-28
 § 13:2.2 Consequences of Suspension and Debarment..... 13-32
 § 13:2.3 Term of Suspension or Debarment 13-33
 § 13:2.4 Grounds for Imposing Debarment or Suspension 13-35

Table of Contents

§ 13:2.5 Factors Informing Agency Discretion to Debar or Suspend 13-37

§ 13:2.6 Debarment or Suspension Based on Imputation or Affiliation 13-40

 [A] Imputation 13-40

 [B] Affiliation 13-41

§ 13:3 Practical Considerations in Addressing Debarment and Suspension for a Firm 13-43

Chapter 14 Money Laundering and Financial Institutions

§ 14:1 Obligations of Financial Institutions in Combating Money Laundering..... 14-2

 § 14:1.1 Overview: Regulatory Framework 14-2

 § 14:1.2 The Money Laundering Control Act 14-4

 [A] Section 1956(a)(1): Conducting Certain Financial Transactions 14-5

 [B] Section 1956(a)(2): Transporting Funds into or out of the United States..... 14-6

 [C] Section 1956(a)(3): “Sting” Operations 14-7

 [D] Section 1957: Money Transactions in “Criminally Derived Property” 14-7

 [E] Penalties for Violations 14-8

 § 14:1.3 The Bank Secrecy Act 14-9

 [A] Financial Institutions Are Required to Implement AML Compliance Programs 14-9

 [B] Financial Institutions Are Required to Implement Adequate Customer Identification Programs 14-10

 [C] Financial Institutions Are Required to File Suspicious Activity Reports..... 14-12

 [D] Financial Institutions Are Required to File Currency Transaction Reports..... 14-14

 [E] Joint Statements on BSA/AML Collaboration and Innovation 14-15

 [F] Penalties for Violations 14-16

 § 14:1.4 The Emergence of the New York Department of Financial Services As a Prominent Regulatory Force 14-18

 § 14:1.5 Interagency Money Laundering Guidance Regarding Foreign Corruption..... 14-20

 [A] Account Opening..... 14-21

 [B] Account Transaction Scrutiny..... 14-23

 [C] Suspicious Activity Reporting 14-24

§ 14:1.6	Special Issues for U.S. Financial Institutions Relating to Foreign Banks Utilizing U.S. Correspondent Accounts.....	14-24
[A]	Money Laundering Risks of Correspondent Accounts.....	14-24
[B]	Payable-Through Accounts.....	14-27
§ 14:2	Money Laundering Enforcement, Penalties, and Trends.....	14-28
§ 14:2.1	Overview and Recent Developments.....	14-28
§ 14:2.2	Penalties for Failing to Maintain an Adequate AML Program	14-29
[A]	Federal Enforcement Actions Following BSA and AML Violations.....	14-29
[B]	DFS’s Prominent Role in AML Enforcement Efforts Against Foreign Banks	14-33
[C]	Focus on Money Services Businesses	14-35
[D]	Increased Scrutiny of Broker-Dealers	14-38
[E]	Personal Liability for BSA/AML Violations	14-40
[F]	Penalties for Structuring to Avoid CTRs	14-42
[G]	The Panama Papers	14-43
§ 14:2.3	Digital Currency, Cannabis and Other Emerging Industries Posing AML Challenges	14-44
§ 14:2.4	Money Laundering by Corrupt Foreign Leaders: Kleptocracy Initiative	14-46
§ 14:2.5	Combating Terrorism Financing	14-48
§ 14:2.6	Violations of Export Controls and Economic Sanctions Can Lead to Money Laundering Issues for Financial Institutions	14-51

Chapter 15 The Foreign Corrupt Practices Act and the International Conventions on Bribery

§ 15:1	Introduction	15-1
§ 15:1.1	Enforcement Statistics	15-2
§ 15:1.2	Trends in Enforcement Policies, Priorities, and Practices	15-7
[A]	Multi-Jurisdictional Cooperation	15-10
§ 15:2	The Foreign Corrupt Practices Act.....	15-12
§ 15:2.1	Who Is Subject to the FCPA?	15-12
§ 15:2.2	Anti-Bribery Provisions.....	15-13
§ 15:2.3	Penalties for Anti-Bribery Provision Violations.....	15-15
§ 15:2.4	Exceptions and Defenses	15-17
§ 15:2.5	Accounting Violations.....	15-20
§ 15:2.6	The Resource Guide	15-25

Table of Contents

§ 15:3 International Cooperation and Anti-Corruption
Enforcement 15-28

§ 15:3.1 International Conventions on Bribery 15-29

§ 15:3.2 The U.K. Bribery Act of 2010 and
U.K. Enforcement 15-31

§ 15:3.3 Brazilian Anti-Corruption Laws and
Enforcement 15-35

**Chapter 16 Prosecutions for Violations of
U.S. Export Controls and Trade Sanctions**

§ 16:1 Introduction 16-2

§ 16:2 Export Controls and Economic Sanctions:
Regulatory Framework 16-3

§ 16:2.1 Office of Foreign Assets Control Regulations 16-3

[A] U.S. Economic Sanctions: History and
Statutory Authority 16-3

[B] Types of OFAC Regulations and Prohibitions 16-7

[C] OFAC Jurisdiction: Who Should Comply? 16-14

[D] OFAC’s Reporting, Procedures and Penalties
Regulations 16-17

[E] OFAC Exemptions and Licensing Procedures 16-19

[F] Challenging an OFAC Designation 16-22

§ 16:2.2 International Traffic in Arms Regulations 16-26

[A] Overview of ITAR Prohibitions 16-29

[B] Licensing Process and Exemptions 16-30

[C] Summary of Part 130 Requirements 16-32

[D] Summary of Section 126.1 Requirements 16-33

[E] Treatment of Dual Nationals/Third-Country
Nationals 16-34

§ 16:2.3 Export Administration Regulations 16-35

[A] Overview of EAR Prohibitions 16-36

[B] Licensing Process and Exceptions 16-37

[C] Anti-Boycott Regulations 16-41

§ 16:2.4 Determining Appropriate Jurisdiction 16-42

[A] Sanctions or Export? 16-43

[B] EAR or ITAR Classification? 16-44

§ 16:3 Enforcement 16-48

§ 16:3.1 OFAC Violations: Penalties and Trends 16-49

§ 16:3.2 ITAR Violations: Penalties and Trends 16-57

§ 16:3.3 EAR Violations: Penalties and Trends 16-61

§ 16:4 Compliance with Export Control Regulations 16-67

§ 16:4.1 Corporate Compliance Programs 16-67

§ 16:4.2 “Know Your Customer” 16-70

§ 16:5 Responding to Violations 16-72

 § 16:5.1 Voluntary Disclosure Prior to Commencement
of a Government Investigation 16-72

 [A] Notification and Documentation
Requirements..... 16-73

 [B] Penalty Enforcement and Mitigation..... 16-73

 [C] The Decision to Disclose Voluntarily 16-74

 § 16:5.2 Defending Export Control Violations in a
Government Investigation 16-76

 § 16:5.3 Due Diligence in Mergers and Acquisitions..... 16-77

Appendices App.-1

Appendix A Yates Memo App. A-1

Appendix B Principles of Federal Prosecution of
Business Organizations..... App. B-1

Appendix C NYCBA Formal Opinion 2004-02 App. C-1

Appendix D DOJ/SEC FCPA Resource Guide App. D-1

Appendix E The Fraud Section’s FCPA Enforcement
Plan and Guidance App. E-1

Appendix F Guidance on Enhanced Security for
Transactions That May Involve Proceeds
of Foreign Official Corruption..... App. F-1

Appendix G Sentencing Guidelines Manual, Chapter 8:
Sentencing of Organizations App. G-1

Appendix H DOJ Corporate Leniency Policy App. H-1

Appendix I DOJ Leniency Policy for Individuals App. I-1

Appendix J SEC Enforcement Manual, Chapter 6:
Cooperation..... App. J-1

Index I-1